Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2023 07:00 ET | Source: PreludeDx

PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium

In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients
November 29, 2023 07:00 ET | Source: PreludeDx

PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 San Antonio Breast Cancer Symposium

PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 SABCS
November 16, 2023 07:30 ET | Source: PreludeDx

PreludeDx™ to Present Multiple Presentations at the 2023 San Antonio Breast Cancer Symposium

PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS).
October 02, 2023 10:17 ET | Source: PreludeDx

UPDATE - PreludeDx Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...
September 19, 2023 07:30 ET | Source: PreludeDx

PreludeDx™ to Present New DCISionRT® Comparative Data in Oral Session at ASTRO 2023 Annual Meeting

LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it...